INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2024

Continued treatment with tirzepatide maintained and further reduced weight, whereas switching to placebo led to substantial weight regain.

In this phase 3 trial, 783 adults completed a 36-week open-label tirzepatide lead-in period with diet and physical activity, achieving a mean weight reduction of 20.9%. At week 36, 670 participants were randomized to continue tirzepatide or switch to placebo for 52 weeks. Mean percent weight change from week 36 to 88 was -5.5% with tirzepatide compared to +14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%]; P < .001). Overall, 89.5% of tirzepatide participants maintained at least 80% of initial weight loss versus 16.6% on placebo. The most common adverse events were mostly mild to moderate gastrointestinal symptoms.

Study type
Phase 3, randomized withdrawal clinical trial
Who was studied
670 adults with obesity or overweight and weight-related complications (excluding diabetes) who completed a 36-week lead-in period
What was measured
Mean percent change in weight from week 36 to week 88

THE PAPER

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.

Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA, SURMOUNT-4 Investigators. JAMA, 2024.

PubMed 38078870 ↗DOI 10.1056/nejmoa1411892 ↗

Weight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.